CHENGDU KANGHONG BIOTECHNOLOGIES CO., LTD.
|CHENGDU KANGHONG BIOTECHNOLOGIES CO., LTD. Patent applications|
|Patent application number||Title||Published|
|20140086904||Humanized Anti-TNF-alpha Antibody and Antigen-Binding Fragment (Fab) Thereof and Use of the Same - The present invention discloses a humanized anti-human tumor necrosis factor-α antibody and antigen-binding fragment (Fab) thereof. The present invention also discloses a composition comprising the said antibody or antigen-binding fragment (Fab) thereof, and the use of the said antibody or antigen-binding fragment (Fab) thereof in treating the diseases associated with tumor necrosis factor-α.||03-27-2014|
|20100272719||Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains - Described herein are novel soluble chimeric fusion proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including domain 4 of KDR. The claimed chimeric fusion proteins antagonize the endothelial cell proliferative and angiogenic activity of VEGF and are useful in the treatment of neovascularization-related disease.||10-28-2010|
|20100215655||ANGIOGENESIS-INHIBITING CHIMERIC PROTEINS AND THE USE - The present invention is directed to DNA sequence encoding angionenesis-inhibiting recombinant chimeric protein, the chimeric protein per se, the pharmaceutical use of the chimeric protein, and to the pharmaceutical composition containing the recombinant protein and the formulation thereof.||08-26-2010|
|20100047208||Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof - The present invention relates to gene therapy for tumors, specifically, it relates to the construction of oncolytic adenovirus recombinant, which specifically expresses immune modulatory factor GM-CSF in tumor cells and uses thereof.||02-25-2010|
|20090264358||VEGF RECEPTOR FUSION PROTEINS, THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS FOR THE EYE DISEASES - Vascular endothelial growth factor (VEGF) receptor fusion protein comprising Ig domain 2 of Flt-1 and Ig domains 3, or Ig domain 2 of Flt-1 and Ig domain 3 and 4 of KDR, the gene encoding the fusion protein, the pharmaceutical composition containing the fusion protein and the pharmaceutical use of the fusion protein are provided. The fusion protein can be used for treatment of eye disorders involving angiogenesis such as diabetic retinopathy.||10-22-2009|
Patent applications by CHENGDU KANGHONG BIOTECHNOLOGIES CO., LTD.